Blood vessel-blocking drug may delay prostate cancer progression
June 9th, 2010 - 2:34 pm ICT by ANIWashington, June 9 (ANI): In a clinical trial of 200 prostate cancer patients, a blood vessel-blocking drug called tasquinimod slowed the rate of disease progression, say experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.
Tasquinimod is a so-called “anti-angiogenesis” drug that squeezes off blood supply to prostate tumors by blocking new blood vessel development. Tumors require these vast networks of blood vessels to supply nutrients.
The multicenter trial at seven institutions, including Johns Hopkins, enrolled prostate cancer patients whose disease had spread to take a once-daily pill for four weeks.
At six months, 57 percent of men taking tasquinimod had no disease progression as compared with 33 percent taking a placebo.
Overall, the drug added approximately 12 weeks of time that the disease did not worsen (progression-free survival).
The most common side effects included gastrointestinal problems, fatigue and bone pain, and some rare occurrences of heart attack, stroke and deep vein thrombosis.
“Given these results, we feel it is reasonable to move forward with Phase III studies. After exploring the drug as a single agent, we may study it in combination approaches with other prostate cancer drugs,” said Michael Carducci, professor at the Johns Hopkins Kimmel Cancer Center, who will lead the next phase of an international study of the drug.
The work was presented at the annual meeting of the American Society of Clinical Oncology (ASCO), June 4-8, in Chicago. (ANI)
- Blocking action of protein blunts serious ill effects of high BP on heart - May 03, 2011
- How breast cancer cells dodge immune system and survive - Feb 02, 2011
- Chemo-Vandetanib combo effective for lung cancer treatment: Study - Jun 06, 2010
- How a vegetarian diet can prevent cancer - Oct 28, 2010
- Nanosized non-invasive probe to see blood vessel growth in tumours - Jul 24, 2010
- Novel method might help block for tumour growth - Mar 15, 2011
- Lowering cholesterol levels may cut prostrate cancer risk - Feb 24, 2009
- Morphine may block tumour growth - Jul 29, 2010
- Heart drug cuts prostate cancer risk - Apr 03, 2011
- Scientists discover new genes for cancer, other diseases in plants, yeast and worms - Apr 14, 2010
- Bone drug may help prevent spread of early lung cancer - Feb 26, 2011
- Potential therapeutic target across a range of cancer types found - Oct 21, 2010
- New treatment shows promise in the fight against breast cancer - Mar 30, 2011
- Exercise improves survival in prostate cancer patients - Feb 02, 2012
- Molecules that help propel cancer metastasis identified - Apr 08, 2011
Tags: american society of clinical oncology, blood vessel development, bone pain, cancer drugs, deep vein thrombosis, disease progression, duke university, free survival, gastrointestinal problems, kimmel cancer center, michael carducci, multicenter trial, park cancer institute, prostate cancer, prostate cancer patients, prostate cancer progression, prostate tumors, rare occurrences, roswell park cancer, roswell park cancer institute